Restore Hyper Wellness
2411 James Street · Bellingham, WA 98225
5.0(155 Google reviews · 55 in past year)
ShiftSetGo Bellingham · 1301 West Bakerview Road · Bellingham, WA 98226
4.9· 16 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
In Bellingham, Washington, ShiftSetGo offers coached weight loss as described on its website: weekly one-on-one coaching, meal replacements, and a Shift Plus option that adds tirzepatide injections, with cryo body sculpting and red light therapy also listed. The site dates the company to 2003 and mentions a board-certified holistic health coach. Because the main service is coaching, ask who prescribes the injections and how visits are supervised. This location has a 4.9-star Google rating across 16 reviews dating back to 2017, with none in the past year, and 8 reviews mention results.
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Yes |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Counts computed by RetaMaps from public Google reviews; most recent review 2025-05-21. Read the reviews themselves on the practice's Google listing.
Rated ★4.9 across 16 Google reviews. Of the 16 reviews we analyzed, 16 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
No negative reviews among those we analyzed.
Stacy E.★★★★★2025-05-21I have been doing Red Light Therapy and have noticed an amazing improvement. Sleeping better, weight loss, less pain. Waiting to see what continues to happen ☺️
Sulene K.★★★★★2022-11-28Mardi & Cheryl are awesome coaches! They care, encourage and have knowledge to help keep me moving forward in my health goals! I highly recommend, not only this location, but this program!
Stacee A.★★★★★2022-06-08I love this program because IT WORKS! I have lost 45 lbs in 4 months. What is great is I don't feel hungry they have delicious bars that are favorite to eat on the go and help if you are craving something sweet!
Sara B.★★★★★2022-03-26This company knows how to help clients focus on healthy eating - for life! It's not a fad weight loss company. Their coaches teach you a nutritional way of eating that is actually good for you and will sustain your weight loss for years, as long as you stick with what you learn while in it. 😉 Food products are delicious and it's a really simple program to follow.
Deep V.★★★★★2021-07-19I appreciate coaches getting back to me quickly.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
2411 James Street · Bellingham, WA 98225
5.0(155 Google reviews · 55 in past year)
2604 Lummi View Drive · Bellingham, WA 98226
500 Birchwood Ave Suite A · Bellingham, WA 98225
5.0(35 Google reviews · 2 in past year)
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs